Assembly Biosciences Cash on Hand 2010-2023 | ASMB
Assembly Biosciences cash on hand from 2010 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Assembly Biosciences Annual Cash on Hand
(Millions of US $) |
| 2023 |
$130 |
| 2022 |
$92 |
| 2021 |
$147 |
| 2020 |
$216 |
| 2019 |
$274 |
| 2018 |
$218 |
| 2017 |
$120 |
| 2016 |
$53 |
| 2015 |
$68 |
| 2014 |
$29 |
| 2013 |
$27 |
| 2012 |
$20 |
| 2011 |
$37 |
| 2010 |
$15 |
| 2009 |
$0 |
Assembly Biosciences Quarterly Cash on Hand
(Millions of US $) |
| 2023-12-31 |
$130 |
| 2023-09-30 |
$46 |
| 2023-06-30 |
$60 |
| 2023-03-31 |
$73 |
| 2022-12-31 |
$92 |
| 2022-09-30 |
$109 |
| 2022-06-30 |
$117 |
| 2022-03-31 |
$123 |
| 2021-12-31 |
$147 |
| 2021-09-30 |
$181 |
| 2021-06-30 |
$199 |
| 2021-03-31 |
$215 |
| 2020-12-31 |
$216 |
| 2020-09-30 |
$238 |
| 2020-06-30 |
$227 |
| 2020-03-31 |
$249 |
| 2019-12-31 |
$274 |
| 2019-09-30 |
$157 |
| 2019-06-30 |
$174 |
| 2019-03-31 |
$194 |
| 2018-12-31 |
$218 |
| 2018-09-30 |
$234 |
| 2018-06-30 |
$93 |
| 2018-03-31 |
$109 |
| 2017-12-31 |
$120 |
| 2017-09-30 |
$66 |
| 2017-06-30 |
$76 |
| 2017-03-31 |
$91 |
| 2016-12-31 |
$53 |
| 2016-09-30 |
$59 |
| 2016-06-30 |
$64 |
| 2016-03-31 |
$58 |
| 2015-12-31 |
$68 |
| 2015-09-30 |
$66 |
| 2015-06-30 |
$71 |
| 2015-03-31 |
$96 |
| 2014-12-31 |
$29 |
| 2014-09-30 |
$18 |
| 2014-06-30 |
$21 |
| 2014-03-31 |
$24 |
| 2013-12-31 |
$27 |
| 2013-09-30 |
$32 |
| 2013-06-30 |
$33 |
| 2013-03-31 |
$37 |
| 2012-12-31 |
$20 |
| 2012-09-30 |
$24 |
| 2012-06-30 |
$29 |
| 2012-03-31 |
$31 |
| 2011-12-31 |
$37 |
| 2011-09-30 |
$53 |
| 2011-06-30 |
$11 |
| 2011-03-31 |
$14 |
| 2010-12-31 |
$15 |
| 2010-09-30 |
|
| 2010-06-30 |
|
| 2010-03-31 |
|
| 2009-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.068B |
$0.007B |
|
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
|
